文章摘要

探讨益赛普治疗强直性脊柱炎的疗效观察及安全性评价

作者: 1田军伟, 1张晟, 1张洁, 1曾静, 1郭乃亮
1 信阳市中心医院风湿免疫科,河南 信阳 464000
通讯: 田军伟 Email: tianjunwei112@126.com
DOI: 10.3978/j.issn.2095-6959.2016.01.009

摘要

目的:观察益赛普治疗强直性脊柱炎的临床疗效,并进行安全性评价。方法:将我院选取的36例强直性脊柱炎患者随机分为观察组与对照组,观察组给予益赛普治疗,对照组给予柳氮磺胺吡啶治疗,疗程为12周。分别于0、4、8、12周进行临床疗效及不良反应情况评价。观察指标主要为ASAS20、ASAS50、ASAS70、脊柱痛、AS活动指数(AS activity index,BASDAI)、胸廓扩张度、脊柱侧弯、晨僵时间、红细胞沉降率(erythrocyte sedimentation rate,ESR)及C反应蛋白(C-reactive protein,CRP)等。结果:与治疗前比较,观察组治疗后各时间点脊柱痛、BASDAI、Schober试验、胸廓扩张度、脊柱侧弯及CRP、ESR等指标水平均明显改善,差异均有统计学意义(P<0.05);与治疗前比较,对照组患者治疗后8、12周脊柱痛、BASDAI、晨僵时间、Schober试验、胸廓扩张度、脊柱侧弯及CRP、ESR均明显改善,差异均有统计学意义(P<0.05);但在第4周时各指标无明显改善,差异无统计学意义(P>0.05);与对照组比较,观察组治疗后其各项观察指标改善程度明显提高,比较差异均有统计学意义(P<0.05)。观察组不良反应发生率为16.7%,较对照组55.6%明显降低,比较差异有统计学意义(P<0.05)。结论:益赛普治疗强直性脊柱炎的临床效果显著,对患者症状、体征、关节功能及生活质量能够明显改善,且安全性较好。
关键词: 益赛普 强直性脊柱炎 疗效

xplore the clinical effect of etanercept for the treatment of ankylosing spondylitis and the safety evaluation

Authors: 1TIAN Junwei, 1ZHANG Sheng, 1ZHANG Jie, 1ZENG Jing, 1GUO Nailiang
1 Department of Rheumatism and Immunology, Xinyang Central Hospital, Xinyang Henan 464000, China

CorrespondingAuthor: TIAN Junwei Email: tianjunwei112@126.com

DOI: 10.3978/j.issn.2095-6959.2016.01.009

Abstract

Objective: To explore the clinical effect of etanercept in the treatment of ankylosing spondylitis and evaluate the safety of this therapy. Methods: 33 cases of patients with ankylosing spondylitis who come to our hospital for treatment were selected and divided into observation group and control group. Patients in observation group was treated with etanercept and patients in control group was treated with willow nitrogen sulfanilamide pyridine and methotrexate. The time for treating is 12 weeks. The curative effect and adverse reaction at 0, 4 , 8 and 12 weeks were evaluated respectively. The relevant observation indexes are mainly ASAS20, ASAS50, ASAS70, spinal pain, AS activity index (BASDAI), thoracic expansion degree, scoliosis, morning stiffness time, erythrocyte sedimentation rate (ESR) and c-reactive protein (CRP). Results: Compared with before receiving the treatment, the level of the indexes of spinal pain, BASDAI, schober test, thoracic expansion degree, scoliosis, CRP and ESR of patients in the control group improved a lot, the difference was statistical significance (P<0.05). Similarly, these indexes in observation group had a great improvement in 8 and 12 weeks, the difference was statistically significance (P<0.05); but the level of these indexes had no statistical significance at 4 weeks (P>0.05). Compared with control group, we found out that all of the indexes been tested had a great improvement than that in the control group, the difference was statistically significant (P<0.05). The rate of adverse reaction of the observation group was 16.7%, which was obviously lower than that of the control group (55.6%), the difference between them had statistical significance (P<0.05). Conclusion: The etanercept has great clinical effect in the treatment of ankylosing spondylitis. It can improve the symptoms, signs, joint function as well as patient’s quality of life, which is safety and worth of popularizing.

文章选项